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Review of the pre- and post-marketing studies of
zonisamide in Japan provides valuable insight into
the optimal use of this drug; in particular, its efﬁ-
cacy in speciﬁc seizure subtypes.
After reviewing the data, Dr. Yagi has teased
out some important distinctions regarding epilepsy
and seizure subtypes. In particular, clinical trial
results for patients who have temporal versus
non-temporal lobe epilepsy are not usually sep-
arated out, as was done in Dr. Yagi’s report. In
animals, hippocampal and non-hippocampal areas
differ in seizure-kindling threshold and density of
receptors; both of which serve as sites of action for
many antiepilepsy drugs (AEDs). In clinical trials,
patients tend to be lumped together for analysis,
and distinctions are not drawn about whether the
agent being studied is more effective in one type
of seizure over another. For this reason it is not
clear whether some AEDs are more effective in
some types of partial seizures. Dr. Yagi’s analysis
provides some useful direction for future reporting
of clinical trial results.
The most remarkable ﬁndings in these stud-
ies of zonisamide are among patients with sec-
ondarily generalized epilepsy. Patients with
atypical absence seizures appeared to do ex-
tremely well on zonisamide. Those with atonic
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seizures and Lennox–Gastaut syndrome also did
well.
In the post-marketing study of newly diag-
nosed patients, there was an excellent efﬁcacy
rate, 93%, in patients with tonic seizures. These
seizures are difﬁcult to control. One area of con-
cern with drugs that have a narrower spectrum of
action than zonisamide, such as gabapentin and
tiagabine, is that patients with generalized seizures
often get worse while taking these agents. Among
zonisamide-treated patients, there were very few
instances of seizures worsening.
The case studies presented are instructive. Clini-
cians usually receive information from clinical trials
that report results for large patient groups; how-
ever, subsets or individual patients often have a re-
markable response to one drug over another, and
this information can be useful. It was interesting to
note that the best results among these three pa-
tients were achievedwith zonisamidemonotherapy.
The addition of zonisamide to the US market
will help to optimize our management of patients
with epilepsy. It will allow us to further expand
our repertoire of drug combinations with comple-
mentary mechanisms of action, as well as to initi-
ate monotherapy with zonisamide in appropriate
situations.
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